Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 251 - 300 out of 97,147

Document Document Title
WO/2014/125277A1
The invention is based on the finding that microparticles can be produced by conditionally- immortalised cells. The conditionally-immortalised cells may be stem cells. The Examples show the successful harvest of microparticles from condi...  
WO/2014/126486A1
The present invention, comprised of the crude aqueous extract of Dioscorea hispida, an indigenous plant from the Philippines, has been shown to have sedative, anti-inflammatory, and analgesic effects. The sedative effect is comparable to...  
WO/2014/127258A3
The invention provides epsilon toxin (ETX) produced by Clostridium perfringens type B or type D as a causative toxin for human multiple sclerosis (MS). The invention further identifies ETX binding receptor MAL for ETX mediated cell death...  
WO/2014/127139A1
This invention provides a method for treating a human subject afflicted with a progressive form of multiple sclerosis, comprising periodically administering to the human subject an amount of laquinimod effective to treat the human subjec...  
WO/2014/127201A1
The present disclosure is generally directed to neuroactive enantiomeric 15-, 16- and 17- substituted steroids with additional optional substituents at carbons 3, 4, 6, 7, 10 and 13, and pharmaceutically acceptable salts thereof, for use...  
WO/2014/125276A1
This invention relates to stem cell microparticles and miRNA isolated from these microparticles, their use and production, in particular neural stem cell microparticles and their use in therapy. The stem cell microparticle is typically a...  
WO/2014/126199A1
[Problem] To provide a novel activity enhancing agent for oxidized protein hydrolase. [Solution] This oxidized protein hydrolase activity enhancing agent is characterized by containing the extract of at least one type of plant selected f...  
WO/2014/124928A1
The invention relates to the use of extracts from Calendula for the treatment and prevention, or therapy and prophylaxis, of disorders and impairments of cognitive and mental functions and for the improvement of mental and cognitive func...  
WO/2014/125121A1
The present application relates to a composition comprising a selective androgen modulating compound of formula (I) and selective estrogen receptor β agonist of formula (II). The present application also relates to the use of a selectiv...  
WO/2014/126191A1
The present invention addresses the problem of providing a drug having a cognitive function improving effect and antidiabetic effect. A phospholipid compound which contains an unsaturated fatty acid having a cyclopropane ring such as 8-[...  
WO/2014/126979A1
The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, wherein R1, R2 and R3 are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, a...  
WO/2014/124560A1
Provided herein are compounds of the formula I: (I), as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions contain...  
WO/2014/126972A1
The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, wherein X is defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therap...  
WO/2014/125340A1
The present invention concerns a liquid smoke composition comprising: propylene glycol and/or sorbitol, glycerine, water and at least one compound useful as a medicament by inhalation. Said composition may be advantageously utilized to s...  
WO/2014/124651A1
The present invention relates to compounds of Formula (I), combinations and use thereof for disease therapy, or pharmaceutically acceptable salt or solvate thereof, including all tautomers, stereoismers and polymorphs thereof, which are ...  
WO/2014/125444A1
Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.  
WO/2014/125397A1
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1 and R2 are as defined in ...  
WO/2014/127315A1
In alternative embodiments, the invention provides nucleophilic hydroxyimino- acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibited human acetylcholinesterase...  
WO/2014/122604A1
Disclosed is an extract of Polygonum fagopyrum for use in the prevention or treatment of a condition, disorder or disease involving a reduction in the endogenous testosterone level in males.  
WO/2014/123186A1
The present invention mainly addresses the problem of providing an antibody against semaphorin 3A protein, said antibody enabling effective prevention and/or treatment of a disease, in which Sema3A protein participates, such as a neurode...  
WO/2014/124013A1
The present invention relates to amino diol derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.  
WO/2014/123151A1
The purpose of the invention is to elucidate the mechanism of onset of MSA through identifying a causative gene, and then to discover a treatment method. The invention provides a method for testing the risk of multiple system atrophy of ...  
WO/2014/122474A1
The present invention provides muscarinic M4 receptor agonists of formula (I) and pharmaceutically acceptable salts thereof, wherein m, n, p, q, R, R2 and R3 are as defined in the specification, processes for their preparation, pharmaceu...  
WO/2014/122405A1
The invention relates to a solid oral pharmaceutical composition containing agomelatine intended for systemic action.  
WO/2014/122184A1
Herein described are deuterated catecholamine derivatives of the general Formula (I) wherein R1 is deuterium, R2, and R3 are independently selected from hydrogen and deuterium and wherein at least one of R2 and R3 has a deuterium enrichm...  
WO/2014/124458A1
Disclosed herein inter alia are compositions and methods useful in the treatment neurodegenerative diseases and cardiomyopathy, and for modulating the activity of PINK1.  
WO/2014/121883A1
The present invention relates to novel acetylene derivatives as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling.  
WO/2014/121885A1
The present invention relates to novel quinoxaline derivatives of formula (I) as positive allosteric modulators for modulating metabotropic glutamate receptor subtype 4 (mGluR4) and/or altering glutamate level or glutamatergic signalling.  
WO/2014/122530A1
Embodiments of the present invention relate to 4-(phenoxymethyl)-1,3-dioxolane analogs and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of Cortisol ...  
WO/2014/120784A1
Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations ...  
WO/2014/120800A1
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations a...  
WO/2014/120786A1
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations a...  
WO/2014/121062A1
Provided herein are HDAC3 inhibitors, as well as methods of treatment comprising administering these compounds to a subject in need thereof.  
WO/2014/120783A1
Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations ...  
WO/2014/118039A1
The present invention relates to radiolabeled compounds of formula (I) wherein R1, R2, R3 and R4 are as defined herein.  
WO/2014/117947A1
The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) in which the chemical groupings, substituents and indices are as defined in the description, and to their use as medicaments, in particular ...  
WO/2014/120789A1
Disclosed are compounds having enhanced potency in the modulation of NMDA receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations a...  
WO/2014/120885A1
The present invention relates to the field of drug abuse. More specifically, the present invention provides methods and compositions for treating drug abuse by preventing GAPDH nitrosylation. In one specific embodiment, a method for prev...  
WO/2014/117680A3
The invention discloses the use of TRPC6 mRNA levels in peripheral blood cells for the early detection/diagnosis of senile dementia. Furthermore, the present invention sets forth the use of a classic transient receptor potential channel ...  
WO/2014/117700A1
The present invention provides a protopanoxadiol derivative of structural formula I or II, a preparation method and an application thereof. The present invention performs structural modification on protopanoxadiol, and obtains multiple n...  
WO/2014/119649A1
 The objective of the present invention is to provide a compound, or a salt thereof, having regulatory activity on the function of lysophosphatidylserine receptors. The present invention provides a compound, or a salt thereof, having...  
WO/2014/117919A1
The present invention relates to novel substituted pyridine derivatives as positive allosteric modulators for modulating metabotropic giutamate receptor subtype 3 (mGluR3) and/or altering giutamate level or glutamatergic signalling.  
WO/2014/117669A1
Disclosed is a benzisoselenazolone-containing donepezil analog as represented by formula I and in either the form of a free radical, the form of a salt or the form of a solvate, also disclosed are a pharmaceutical composition comprising ...  
WO/2014/118133A1
The present invention relates to new kinase inhibitors of Formula (I) or a stereoisomer, tautomer, racemic, salt, hydrate, or solvate thereof, and more specifically to ROCK inhibitors, compositions, in particular pharmaceuticals, compris...  
WO/2014/117670A1
The present application provides a styryl quinoline compound represented by formula I and the use thereof in a pharmaceutical composition for treating, improving, and/or preventing Alzheimer's disease. R1-R7 are as defined in the descrip...  
WO/2014/120658A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A5, A6, A8, R1, R2, R3, R7, X, Y, n and o of Formula I,...  
WO/2014/118307A1
The present invention relates to novel crystal forms of 4-(6-ethoxy-1-methoxy-thioxanthene-9-ylidcne)-1-methyl piperidine salts and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine salts; especially to novel crystal form...  
WO/2014/120994A1
The present invention provides compounds of formula I or a salt, solvate, or stereoisomer thereof, wherein X is H, or an electron withdrawing group such as a halogen, NH2, NO2, SO2, CN, or a C1-C6 alkyl group; Alk is C1-C3 alkyl; R1 is H...  
WO/2014/117680A2
The invention relates to the use of TRPC6 mRNA levels in peripheral blood cells for the early detection/diagnosis of senile dementia. Specifically, the present invention provides a classic transient receptor potential channel 6 (TPRC6) g...  
WO/2014/117863A1
The present invention relates to novel crystal forms of 4-(6-ethoxy-l-methoxy-thioxanthene-9- ylidene)-1-methyl piperidine salts and 4-(6-ethoxy-1-hydroxy-thioxanthene-9-ylidene)-1-methyl piperidine salts; especially to novel crystal for...  

Matches 251 - 300 out of 97,147